Category: Uncategorized

A normal or noncontributory anatomical examination did not exclude diphenhydramine poisoning in five reported infant deaths. The investigators combined postmortem toxicology with scene information, other examinations and, in two cases, admissions of administration. The report did not establish that any positive drug finding automatically determines cause of death.

Five infants with otherwise unexplained deaths

Baker and colleagues described infants aged six, eight, nine, twelve and twelve weeks. This was a selected five-case report, not a consecutive population survey, controlled dosing study or estimate of poisoning prevalence. The infants could not have independently obtained and administered the medication.

Gross examinations found no natural disease or injury explaining death. Microscopy and other investigations were negative or noncontributory, apart from pulmonary congestion noted in the six-week-old. The absence of a diagnostic lesion did not establish a nontoxicological explanation.

The postmortem blood diphenhydramine results were 1.6 mg/L at six weeks, 1.5 mg/L at eight weeks, 1.6 mg/L at nine weeks, and 1.1 mg/L in each twelve-week-old. These measured concentrations were observations from individual deaths, not validated age-specific thresholds.

The evidence was more than an unexplained number

In the nine-week-old’s case, the father subsequently admitted administering a diphenhydramine-containing sleep aid to make the child sleep. That history supplied exposure information independently of the blood measurement. The report did not provide a controlled reconstruction of the absorbed dose from that concentration.

In one twelve-week-old’s case, the daycare provider admitted administering diphenhydramine. A feeding bottle also tested positive despite having been cleaned and dried before police seized it. This corroborated exposure; it did not measure the concentration in the bottle before cleaning or the amount the infant consumed.

Only two of the five investigations had an admission of administration. The absence of an admission in the others was not equivalent to a negative toxicology result. Equally, a drug result could not identify a particular administrator without additional evidence.

Why an initial SIDS interpretation could change

The eight-week-old’s death was initially classified as sudden infant death syndrome. After a blood result of 1.5 mg/L, the reported cause was amended to diphenhydramine intoxication. Another case was initially pending and believed to be SIDS before toxicology contributed to a poisoning conclusion.

The authors attributed all five deaths to diphenhydramine after considering the entire investigation. They discussed and rejected an incidental-drug explanation in these cases. That was their case assessment; the series did not validate an automatic rule replacing investigation with a concentration cutoff.

Specimen and method limits remain important

Table 1 identified heart blood at 1.5 mg/L and inferior vena cava blood at 1.3 mg/L in the eight-week-old. Most other blood sites were unspecified. The paper did not provide a uniform death-to-collection interval, detailed storage history, analytical validation, detection limit or quantification limit for all five cases.

Drug and volatile screening was performed. No other substances were detected except trace desmethyldiphenhydramine in one case. That statement describes the reported testing; it is not proof that every possible toxicant was excluded.

Additional results included brain and liver in one infant, spleen, liver and kidney in another, and urine and vitreous in the nine-week-old. Tissue concentrations used mg/kg and fluids mg/L. None supplied a validated blood-equivalent conversion or recovered concentration during life.

What the report supports

The authors argued that toxicology should be part of unexplained infant-death investigations because anatomical examination alone can miss a poisoning explanation. They did not estimate the frequency of such events or directly demonstrate the terminal physiological mechanism in each infant.

Preserve the specimen site, measured result, analytical scope and independent exposure evidence. Neither normal anatomy nor drug detection alone settles causation. A separate, later series illustrates the contrasting problem of diphenhydramine detections considered incidental in some pediatric deaths.

Primary source

Baker AM, Johnson DG, Levisky JA, et al. Fatal Diphenhydramine Intoxication in Infants. Journal of Forensic Sciences. 2003;48(2). doi:10.1520/JFS2002121.

Choosing an unfavorable option does not necessarily mean deliberately seeking risk. The choice may depend on what a participant learned, how probabilities were understood and how feedback was used. A 2007 review of amphetamine and opiate dependence explains why the name of a gambling task is not enough to identify the psychological process behind its score.

Ersche and Sahakian synthesized neuropsychological research involving chronic drug use, including amphetamine and methamphetamine. This was a historical narrative review, not a new randomized drug-administration experiment. Its discussion draws on different participant groups and task designs. It supplies no single pooled sample or effect estimate for “risk taking.”

What must a participant learn in the Iowa Gambling Task?

The Iowa Gambling Task requires a sequence of card choices from decks with different gain and loss patterns. Participants discover the consequences through experience. A common summary is the number of choices from advantageous decks minus choices from disadvantageous decks.

That net score combines choices across the task. It does not separately identify whether performance reflected learning the deck contingencies, remembering previous outcomes, responding to losses or preferring uncertain rewards. A person who has not learned which deck is advantageous can make an unfavorable choice without knowingly preferring its risk.

The review found inconsistent results across drug-use studies. Some reported no measurable impairment. Others found smaller but still positive net scores, while negative net scores appeared in particular subgroups. A smaller positive score should not be recast as a universal preference for disadvantageous decks.

Why use a task with explicit probabilities?

The Cambridge Gamble Task and a related Risk Task were developed to examine decisions with less dependence on learning hidden reward contingencies. In the Cambridge task, relevant probabilities and reward information are provided, and participants make choices and place bets. Trials are independent of previous trials.

These features help separate questions that can be intertwined in the Iowa task. Choosing the more likely option is different from adjusting a bet to the odds. Two participants may make the same option choice while staking very different amounts. Conversely, they may choose differently while adjusting bets similarly.

Questions that gambling-task measures can distinguish

Measure	Question it addresses	What it does not establish alone
Net advantageous card selections	Which decks were selected across a learning task?	Why the participant selected them
Choice of a more probable outcome	Was the option favored by the displayed odds selected?	How much the participant was willing to wager
Adjustment of wagers to risk	Did betting change as the odds changed?	Whether hidden contingencies were learned in a different task
Choice after a loss	Did recent unfavorable feedback affect the next decision?	A general trait governing all decisions outside the laboratory

What did the amphetamine comparison show?

One Cambridge-task study described in the review found that chronic amphetamine users selected the likely, small-reward option on 85% of trials, compared with 92% for opiate users and 95% for controls. Those percentages describe trials within the studied groups, not the percentage of participants diagnosed with impaired judgment.

The review reports no impaired risk adjustment in the amphetamine group. Participants did not increase their wagers on less favorable options or significantly choose against the odds under the risky conditions. The authors therefore considered difficulty estimating outcome probabilities as an explanation, rather than assuming the finding demonstrated greater reward seeking.

That explanation remains an interpretation of task performance. It should not become proof of the mechanism in every participant or a causal conclusion that amphetamine exposure produced the difference. These were comparisons involving people with drug-use histories, with the limitations of such comparisons.

Were all reported choice differences significant?

No. In another imaging study summarized in the review, the most favorable option was selected on approximately 72% of trials by amphetamine users, 82% by opiate users, 79% by former users and 87% by controls. The reported behavioral difference was not statistically significant, although imaging differences were found.

Numerical ordering alone does not establish a reliable behavioral group difference. A brain-activation difference also does not retrospectively turn a nonsignificant choice comparison into a significant one. Imaging and behavior are related measurements, but each needs its own result and uncertainty.

Can feedback findings be assigned to every drug group?

The review describes different feedback patterns across drug-use groups and circumstances. In one comparison, a greater tendency to make risky decisions after an unsuccessful trial occurred specifically in methadone-maintained opiate users. Amphetamine users, street-heroin users and former users did not show that same abnormal response in the account provided.

A finding in an opioid-maintenance subgroup should not become a generic “drug users ignore punishment” claim, much less a methamphetamine-specific conclusion. Drug identity, current treatment, task structure and participant characteristics remain part of the evidence.

What is the practical scientific limit?

A gambling score can help investigate selected components of decision-making. It does not establish that an individual wanted to cause harm, knew a particular real-world risk or acted because of a drug. The laboratory task must first be identified, along with its learning demands, scoring rule, group comparison and null findings.

The review does not provide a known-dose amphetamine exposure, a specimen concentration or a validated impairment threshold for the gambling findings discussed here. It cannot be used to convert a drug-positive test into a conclusion about a person’s intent or decisions at an unrelated event. Its useful lesson is to explain the measured component rather than letting the broad label “risk taking” carry an unsupported inference.

Scientific source

Ersche KD, Sahakian BJ. The neuropsychology of amphetamine and opiate dependence: implications for treatment. Neuropsychology Review. 2007;17(3):317–336. doi:10.1007/s11065-007-9033-y. Full-text author manuscript. Historical narrative review. Individual gambling experiments are described through this supplied source; their primary datasets were not independently reanalyzed.

Choosing a methamphetamine-containing solution and moving more after repeated exposure are different findings. A 2022 review of Drosophila research describes experiments in which feeding preference and locomotor sensitization did not simply increase together. Those results illustrate the value of an animal model while limiting the claim that any one fly behavior is a direct measure of human addiction.

Philyaw, Rothenfluh and Titos reviewed assays used to investigate psychostimulant responses in fruit flies. This was a narrative preclinical review, not a human trial, diagnostic study or new experiment with a single common sample size. The individual experiments below are discussed through that review.

What does a capillary feeding assay measure?

In a capillary feeder assay, flies consume liquid food from narrow tubes. Investigators track displacement of the liquid to estimate consumption over time. A two-choice version offers different solutions and measures their relative consumption. Depending on the setup, researchers can examine cumulative intake, intake rate and preference.

Preference is therefore a behavioral comparison under specified alternatives. It is not a clinician’s diagnosis of a substance-use disorder, a measure of craving reported by a person or a direct blood concentration. The nutrient solution, drug concentration, observation interval and prior exposure all help define the result.

Why is concentration essential?

The review describes flies developing preference for a sucrose solution containing 1 millimolar amphetamine by the first measurement at 24 hours. With 10 millimolar amphetamine, preference instead favored the sucrose solution without drug. In a methamphetamine experiment, preference for 1 millimolar methamphetamine developed after one day, while the 10 millimolar solution was avoided.

These are concentrations in the offered solutions. They are not concentrations measured in fly blood, human blood or brain tissue. A solution concentration alone does not give the amount each animal consumed. A body-weight dose would require additional information about consumption and the animals; absorbed exposure requires further pharmacokinetic information.

The concentration-dependent reversal also prevents describing these experiments as evidence that flies always prefer more stimulant. A finding at one concentration cannot be generalized to every concentration or interpreted independently of the alternative offered.

How did another experiment combine feeding with movement?

The review describes a modified activity-monitor setup in which flies had access to 100 millimolar sucrose and the same sucrose solution supplemented with methamphetamine. Among the concentrations tested, the strongest preference was reported for 0.15 mg/mL methamphetamine. Preference was evident by day two and remained stable during the rest of a seven-day assay.

The 0.15 mg/mL figure describes a different experimental preparation from a result expressed as 1 millimolar. Without matching the chemical form and protocol, the numbers should not be treated as proof of equivalent administered or internal doses. Neither number is a human toxicological threshold.

Activity monitors use infrared beam crossings to quantify movement. Repeated measurements of the same fly improve temporal resolution, but do not turn every beam break into an independent animal. Movement is the endpoint; it cannot substitute for every other behavior relevant to drug use.

Did locomotor sensitization predict greater preference?

Not in the simple way that claim suggests. The review reports increased locomotor activity after exposure to 75 micrograms of vaporized methamphetamine, with activity more than doubling after a second exposure ten hours later. This increased response to repeated exposure is locomotor sensitization.

When these sensitized flies were transferred to the capillary feeding setup, preference no longer developed during the three-day measurement period. In the reverse sequence, flies that had developed preference during three days of feeding did not develop sensitization after the second 75-microgram vapor exposure.

The vapor figure describes the reported exposure preparation. The review does not establish that 75 micrograms entered each fly’s body. Treating it as an absorbed dose per animal would add an unsupported inference.

These observations support studying how exposure history links the two behaviors. They do not support an assumption that stronger sensitization necessarily means stronger voluntary preference. They also do not establish that either response protects a person from addiction or predicts a clinical outcome.

Why does administration route change interpretation?

The review identifies tradeoffs among oral feeding, injection and vapor exposure. Drug-supplemented food permits behavior with relatively little disruption, while offering less control over delivery speed and dose. Injection gives tighter control over the administered dose but is time-consuming and disturbs ordinary behavior. Vapor delivery can coordinate exposure while movement continues to be recorded.

A route comparison is therefore about more than convenience. Exposure speed, precision and the procedure’s effects on behavior can all influence what the assay detects. Findings from different methods should retain their actual route rather than becoming interchangeable “methamphetamine-treated fly” results.

What can this model contribute to human research?

Fruit flies permit genetic manipulations and repeated behavioral assays that can help identify mechanisms for further investigation. Shared dopamine-related processes provide a biological rationale for that work. Similarity of selected pathways, however, does not make a fly’s food choice equivalent to the human disorder.

The review brings together different drugs, genotypes, assays and protocols; it provides no single pooled denominator or universal effect estimate for the experiments described here. Sample sizes and uncertainty for a particular primary experiment would need to be recovered from that experiment before a quantitative reanalysis.

The defensible use is mechanistic and conditional: identify the species, offered concentration, route, exposure history and measured behavior. These experiments neither diagnose human methamphetamine dependence nor establish an individual’s impairment, dose history or responsibility for an event.

Scientific source

Philyaw TJ, Rothenfluh A, Titos I. The Use of Drosophila to Understand Psychostimulant Responses. Biomedicines. 2022;10(1):119. doi:10.3390/biomedicines10010119. Full-text review. Historical preclinical narrative review; feeding and vapor experiments are summarized through this supplied source, not represented as independently reviewed human evidence.

An association between ADHD treatment and later substance use cannot, by itself, show that treatment caused or prevented that outcome. ADHD-related characteristics, co-occurring conditions, the age treatment began and the medication actually used all affect the comparison. A historical 2009 review illustrates why the phrase “stimulant treatment” can conceal substantial differences in evidence.

Berman and colleagues reviewed potential adverse effects of amphetamine treatment on brain and behavior. Their discussion of later substance use considered human observational follow-up, surveys and animal studies. It was not a randomized long-term trial assigning children to amphetamine or no treatment and then measuring adult addiction. Its account should be read as evidence available at that time, not current prescribing guidance.

What was the underlying causal question?

The question was whether exposure to a prescribed stimulant changed later substance-use risk beyond the risk associated with ADHD and related characteristics. A comparison between treated people with ADHD and people without ADHD does not isolate that treatment effect: diagnosis and treatment differ together.

Comparison with untreated people who also have ADHD addresses a closer question, but treatment may still be associated with severity, co-occurring conduct problems, access to care or family circumstances. These are possible alternative explanations requiring measurement and analysis, rather than assumptions that automatically invalidate or resolve the association.

Did all follow-up studies point in one direction?

No. The review described reports suggesting increased later risk, reports suggesting no change and reports suggesting protection. It stated that most studies it discussed, including a meta-analysis, found no effect on subsequent substance abuse or a lower risk. That historical summary does not supply a single causal estimate specific to amphetamine.

One prospective study summarized by the authors followed 112 White male participants with ADHD, initially aged 6–17 years, for ten years. Mean age at follow-up was approximately 22. The review reports no increase or decrease in the frequency of substance-use disorders associated with stimulant treatment, compared with ADHD participants not treated with stimulants.

It also reports an association with 1.6 additional years of alcohol abuse among the subgroup with alcohol abuse, p = 0.04. A subgroup finding about duration and an overall finding about the frequency of disorders answer different questions. Neither should be deleted to make the study appear uniformly protective, harmful or null.

Was the other prominent follow-up study an amphetamine study?

The review describes a different cohort of 176 methylphenidate-treated boys with ADHD, without conduct disorder, and 178 comparison participants without ADHD. Reassessment occurred in late adolescence and early adulthood, with mean ages of 18.4 and 25.3 years. Methylphenidate is a different drug from amphetamine, even though both are prescription stimulants.

The reported lifetime substance-abuse-disorder rates were 44% among ADHD participants who initiated treatment after age seven, 27% among those who initiated before age eight and 29% in the non-ADHD comparison group. These are percentages for different groups within that study, described through the review. They are not the risks attributable to amphetamine or predictions for an individual child.

The age-at-initiation association is scientifically relevant, but the treatment was not randomly started at alternative ages. Timing can be linked to other features of the child, disorder or care. Moreover, the review notes that 98% of this sample began treatment by age 11. This dataset therefore offered little basis for evaluating initiation during college or later adolescence.

Why do medication categories matter?

A review about amphetamine may discuss methylphenidate studies, mixed stimulant histories and animal exposure experiments to explore related questions. That broader context should not be mistaken for an amphetamine-only evidence base.

Evidence distinctions in the historical review

Evidence type	Useful question	Boundary
ADHD participants with and without a treatment history	How later outcomes differed in the observed groups	Treatment selection may differ between groups
Methylphenidate-treated cohort	Associations involving that medication and treatment timing	Does not establish an amphetamine-specific effect
Non-ADHD comparison group	Outcome differences relative to people without ADHD	Diagnosis and treatment are not independently isolated
Animal exposure experiment	Behavioral or biological responses under an assigned regimen	Does not directly measure adult human substance-use disorders

Do animal sensitization findings settle later human addiction risk?

The review discusses developmental differences, sensitization and later responses to drugs in animals. Those experiments can investigate mechanisms under controlled exposure conditions. Sensitization, however, describes an increased response after prior exposure; it is not interchangeable with a human diagnosis of a substance-use disorder.

The authors emphasize that exposure pattern and developmental stage can change animal findings. A result from one species, age or regimen cannot resolve the clinical association simply because the administered compound belongs to the stimulant class. Conversely, an observational human association does not identify the neural mechanism demonstrated in an animal experiment.

What can this evidence support in a client explanation?

It supports asking a more precise question than whether “stimulants lead to addiction.” Identify the medication, age at initiation, diagnosis, comparison group, follow-up interval and outcome definition. Distinguish lifetime disorder prevalence from duration among affected participants, and prescription exposure from later nonmedical use.

The review’s mixed historical findings do not justify treating a later disorder as proof that a prescription caused it. They also do not justify promising that a particular person’s treatment prevented later misuse. A case-specific causal opinion requires more than a medication history followed by an outcome.

This commentary addresses interpretation of historical research. It does not recommend starting, stopping or changing medication, and it does not establish present treatment standards.

Scientific source

Berman SM, Kuczenski R, McCracken JT, London ED. Potential adverse effects of amphetamine treatment on brain and behavior: a review. Molecular Psychiatry. 2009;14(2):123–142; published online August 12, 2008. doi:10.1038/mp.2008.90. Full-text author manuscript. Human cohort results are described through this supplied narrative review; the underlying datasets were not independently reanalyzed. The journal also published a 2010 correction to a separate psychosis-study passage, not the follow-up findings discussed here.

Two different estimates of college stimulant use may both be accurately quoted while measuring different things. A lifetime report is not a past-month report; nonmedical prescription-stimulant use is not necessarily amphetamine use; and use intended to help studying does not demonstrate better academic performance. A 2011 review by Smith and Farah explains why these distinctions belong beside the percentage.

This is historical evidence. The review describes surveys and experiments available at that time. Its estimates should not be presented as the prevalence on today’s campuses, or used to infer whether a particular student consumed a drug.

What did this review examine?

The authors examined both the epidemiology of nonmedical prescription-stimulant use and controlled evidence about cognition in healthy people. The prescription drugs of principal interest were methylphenidate and amphetamine formulations, including dextroamphetamine. They are not interchangeable exposures, and the review did not administer a new drug regimen to one pooled student cohort.

Its survey section identified at least 25 college-student studies by the end of 2009. These differed in geographical coverage, recruitment, sample size, response rate, drug questions and the interval participants were asked to recall. The presence of numerous surveys does not make every percentage an estimate of the same underlying quantity.

How much difference does the recall interval make?

The review describes a 2001 survey of 10,904 students at 119 public and private US colleges and universities. It reported lifetime nonmedical prescription-stimulant use of 6.9%, past-year use of 4.1% and past-month use of 2.1%. These are three estimates from the same survey, as summarized by the review.

Time windows in the historical 10,904-student survey

Reported window	Estimate	Interpretive boundary
Lifetime	6.9%	Does not mean use continued into the survey month
Past year	4.1%	Does not specify regular or daily use
Past month	2.1%	Does not specify a dose, concentration or event-time impairment

The estimates concern the prescription-stimulant category used in that survey. They should not be relabeled as methamphetamine prevalence or the percentage of students misusing amphetamine specifically. The study year is part of the finding, not optional background.

Does “nonmedical” always mean the same thing?

No. Some studies excluded everyone with a prescription from the nonmedical-use group, regardless of how or why the person took the drug. Others classified use by purpose and could count nonmedical use by someone who also had a prescription. One study in the review did not specify its definition.

Those rules can classify the same hypothetical behavior differently. A prescription holder taking medication outside the intended medical purpose may be excluded under the first rule and included under the second. Comparing the resulting percentages without the rules risks treating a measurement difference as a behavioral difference.

Drug coverage also matters. A question naming only Ritalin need not capture other methylphenidate brands, and a broad stimulant question can encompass substances outside the review’s prescription-drug focus. The authors noted that historical national surveys sometimes grouped prescription stimulants with other stimulants, including methamphetamine. An estimate from that combined category cannot establish the rate for each component.

Can a high percentage from one campus represent all students?

A sample’s size does not resolve every question about whom it represents. Some reviewed studies covered multiple institutions; others recruited within a single campus or even classes in one department. Fraternity-only samples addressed a selected student group. The review also reported wide variation in response rates, including approximately 93.8% in one survey and 10% in another.

A low response rate raises the possibility that respondents differed from nonrespondents. A high response rate within a selected class still does not turn that class into a representative national sample. Recruitment frame and participation are separate parts of generalizability.

The review similarly cautioned against treating a voluntary magazine-reader poll on cognitive enhancement as population prevalence. People choosing to answer a topic-specific poll may have unusual interest or experience. That observation challenges generalization from the poll; it does not prove the direction or exact size of its selection bias.

Does past-year use mean frequent use?

No. The survey literature described sporadic as well as more frequent use. Some students reported taking stimulants around examinations; other respondents used more regularly. A past-year yes/no item can place both patterns in the same category.

Frequency among people who reported use also has a different denominator from prevalence among all surveyed students. For example, a percentage describing weekly use within a user subgroup should not be applied to an entire campus. Nor does an episode count identify tablet strength, formulation, route or measured exposure.

Does a study-related motive establish cognitive benefit?

Students commonly reported concentration, studying, memorization, alertness or grades as motives. Surveys also recorded recreational use, staying awake, appetite-related motives and other reasons. Motive categories could overlap.

These answers describe the respondents’ purposes and beliefs. They do not measure how much was learned, establish a higher examination score or show that a pharmacological effect caused improved work. Smith and Farah treated controlled, masked drug–placebo experiments as a separate evidentiary question. Their cognitive review concerned oral methylphenidate or dextroamphetamine in nonelderly adults, with task-specific findings and uncertainty; it did not validate every reported student benefit.

How should an estimate be explained to a client?

Identify the drug category, population, collection year, recall window and definition of nonmedical use before drawing a comparison. Then distinguish prevalence among all respondents from frequency among users and motivation among those reporting a particular purpose. Keep self-report limitations visible.

These historical surveys can explain patterns of reported behavior and the difficulty of measuring them. They cannot diagnose an individual’s drug use, dependence, impairment or responsibility for a specific event. That inference would require evidence about the individual rather than a campus-level percentage.

Scientific source

Smith ME, Farah MJ. Are Prescription Stimulants “Smart Pills”? The Epidemiology and Cognitive Neuroscience of Prescription Stimulant Use by Normal Healthy Individuals. Psychological Bulletin. 2011;137(5):717–741. doi:10.1037/a0023825. Full-text author manuscript. Historical review; survey findings above are described through this supplied review, rather than presented as independently reanalyzed primary data.

Sixty-four effect sizes are not 64 independent exercise trials. In a 2025 systematic review addressing executive function in drug addiction, repeated outcomes from 11 randomized trials contributed to a three-level meta-analysis. Most listed trials involved methamphetamine dependence. The distinction matters when the length of a forest plot is used to suggest a larger body of independent evidence than actually exists.

The review reported a favorable average effect on executive-function measures. Interpreting that finding requires preserving the hierarchy of observations, the nature of the tests and several inconsistencies in the published report. These are questions about the strength and applicability of a synthesis, not reasons to replace its positive findings with an unsupported conclusion of no benefit.

What evidence was eligible?

Chen and colleagues searched Embase, Scopus, PubMed and Web of Science, updating the search through April 30, 2025. They included English-language, peer-reviewed randomized controlled trials in people diagnosed with drug addiction or substance use disorder. Exercise was the principal intervention; comparisons included health education, routine treatment or quiet sitting. Animal studies were excluded from the clinical synthesis.

The 11 trials were published between 2017 and 2024. Activities included aerobic exercise, tai chi and aerobic exercise combined with attentional bias training. Protocols ranged from a single session to 12 weeks, with sessions lasting 20–60 minutes. This was rehabilitation research, not a controlled experiment administering a known methamphetamine dose to test acute intoxication.

Why did 11 trials produce 64 effect sizes?

A trial can supply several measurements: accuracy and reaction time on the same task, different executive tasks, more than one assessment time, or separate active arms sharing a control group. Those measurements are related because some come from the same participants or comparison groups. Counting them as independent replications would misdescribe the evidence.

The authors used a three-level random-effects model to accommodate dependence. Its levels represented sampling variance, variation among effect sizes within a study and variation between studies. This is a methodological response to correlated results; it does not transform one participant cohort into multiple independently randomized cohorts.

The source’s table also changes the meaning of its count symbol. Table 1 uses k for included studies; Table 3 explicitly defines k as extracted effect sizes. Thus the 62 entries in the methamphetamine subgroup of Table 3 are effect sizes, not 62 trials or 62 patients.

What was the estimated benefit?

The overall analysis reported Hedges’ g = 0.40, with a 95% confidence interval of 0.28–0.53, from 64 effect sizes across 11 trials. Hedges’ g is a standardized group contrast. A value of 0.40 does not mean that 40% of participants recovered, that cognition improved by 40%, or that 40% achieved abstinence.

Executive-function estimates reported in the 2025 review

Domain	Extracted effect sizes	Hedges’ g	95% confidence interval
Inhibitory control	34	0.25	0.09–0.42
Cognitive flexibility	10	0.58	0.27–0.88
Working memory	20	0.57	0.34–0.79

The domain moderator test was statistically significant, F = 3.360, p = 0.041. These findings support an outcome-specific account rather than a single claim that every executive ability changed equally. The tasks and their scoring remain relevant to what the pooled estimates mean.

How stable was the pooled result?

The authors identified an outlying working-memory result involving reaction time on the five-number Sternberg task after an eight-week intervention. Excluding that outlier changed the pooled estimate from g = 0.42, 95% CI 0.28–0.56, to g = 0.40, 95% CI 0.28–0.53. That modest change supports numerical stability under that particular sensitivity analysis.

It does not eliminate other uncertainty. The main overall analysis reported moderate heterogeneity, I² = 57.33%, attributable to between-study variation; the within-study variance test was nonsignificant. Four included trials were rated at high risk of bias. A statistically significant average can coexist with differences in trial quality, populations and protocols.

The multilevel Egger test did not detect publication bias, p = 0.180. A nonsignificant bias test should be reported as failure to detect the pattern tested, rather than proof that no studies or unfavorable outcomes were missing.

Why does the participant denominator need qualification?

The abstract and results describe 906 participants, while the discussion describes 809. Table 1 contains an additional inconsistency in one three-arm trial: its listed arm sizes are 24, 23 and 23, which sum to 70, while its sex column reports 60 men. These discrepancies prevent presenting one total as independently reconciled from the report.

Substance labels also conflict. The prose describes one heroin study and ten morphine studies, but Table 1 identifies the other ten as methamphetamine studies. Table 3 likewise labels its larger substance subgroup methamphetamine. This commentary follows the explicit table labels when describing the relevance to methamphetamine, while flagging the conflicting prose. It does not silently substitute morphine, an opioid, for methamphetamine, a stimulant.

Table 3 gives the methamphetamine subgroup estimate as g = 0.40, 95% CI 0.26–0.53; nearby prose gives g = 0.39, 95% CI 0.24–0.53. An exact subgroup quotation should identify which location supplied it. Resolving these differences would require clarification or examination of the underlying extraction and analyses, beyond simply copying the abstract.

Can the review determine an individual’s recovery or impairment?

No individual diagnostic threshold follows from a standardized group average. Better Stroop, working-memory or switching performance under a study protocol does not establish restoration of all everyday functioning, durable abstinence or fitness to drive. Those outcomes require their own measurements and appropriate follow-up.

The synthesis also supplies no methamphetamine blood, urine or oral-fluid concentration that diagnoses impairment. It concerns people with a diagnosed disorder in intervention studies, not a concentration–performance calibration at a specific incident time.

The useful conclusion is qualified: this historical synthesis reported an encouraging average executive-function signal, based on 11 trials with dependent outcomes, heterogeneous protocols, risk-of-bias concerns and unresolved reporting discrepancies. The number of plotted estimates should not inflate the number of independent studies or conceal uncertainty in the population being summarized.

Scientific source

Chen J, Wang X, Zhang X, Xiao W, Kabachkova A, Tan Y. Effects of exercise on executive function in individuals with drug addiction: a systematic review and three-level meta-analysis. Frontiers in Sports and Active Living. 2025;7:1646327. doi:10.3389/fspor.2025.1646327. Historical human-trial synthesis; search coverage through April 30, 2025. Numerical discrepancies described above are present in the supplied report; no participant-level reanalysis was performed.

Cardiovascular drugs did not share a single postmortem concentration pattern in a paired hospital-to-mortuary study. Atenolol and verapamil had statistically significant increases, while diltiazem’s median ratio was below one. Neither result supplied a universal correction to a concentration during life.

What specimens were compared?

Mantinieks and colleagues compiled 811 hospital-death coronial cases from Victoria, Australia, during 2009–2017, reporting 42 drugs and metabolites with at least ten paired results each. The cardiovascular drugs had separate, much smaller denominators.

Earlier clinical material could be whole blood, plasma or serum. The institute generally selected specimens closest to hospital admission, not necessarily closest to death. Approximately 35% of earlier specimens overall were plasma or serum.

Postmortem material was approximately 2–5 mL of femoral blood obtained by leg puncture at mortuary admission, preserved with 1% w/v sodium fluoride and potassium oxalate, stored at 4°C and typically analyzed within 24 hours. Earlier specimens were typically stored at −20°C after receipt.

The five drugs had different paired distributions

Postmortem/antemortem ratios in Table I. Ratios are dimensionless.

Drug	Pairs	Median ratio	Range	Paired p-value
Atenolol	35	1.8	0.23–5.9	0.002
Verapamil	25	1.5	0.07–3.8	0.04
Propranolol	11	1.4	0.06–42	>0.05
Sotalol	11	1.3	0.22–2.8	>0.05
Diltiazem	13	0.69	0.09–5.4	>0.05

The study used a significance level of 0.05. Thus only atenolol and verapamil had significant paired increases among these drugs. A median above one did not automatically mean a significant result; diltiazem’s median below one did not establish a significant decrease.

The atenolol group had median earlier and postmortem concentrations of 0.20 and 0.29 mg/L. Verapamil medians were 0.15 and 0.17 mg/L. These concentration medians must remain separate from the median of individual ratios. Dividing group medians does not reproduce that statistic.

Hospital treatment was an unresolved influence

The authors could not reliably establish whether these drugs were administered in hospital. A substance might have been incompletely absorbed at the first collection, or administered after it. Missing medication records prevented isolation of postmortem redistribution from the whole interval’s other influences.

For atenolol, the median earlier-collection-to-death interval was 22 hours and the median death-to-postmortem-collection interval 20 hours. For verapamil, the corresponding intervals were 27 and 18 hours. These were not experiments holding the predeath concentration constant while varying only postmortem time.

Diltiazem’s lower median did not prove hydrolysis

The authors discussed potential in-vitro hydrolysis to desacetyldiltiazem as an explanation for the lower diltiazem ratio. That was a possible mechanism, not a measured causal allocation in these 13 people. The wide ratio range also included later values above earlier ones.

Unequal partitioning between plasma or serum and whole blood, individual pharmacokinetics and unknown last-dose times complicated interpretation. Blind femoral puncture was another acknowledged sampling limitation. Bodies were not obviously traumatized, burned or decomposed, limiting extrapolation to those circumstances.

Analytical measurement did not establish causation

The investigation used validated LC–MS/MS procedures and referred to earlier analytical publications. It did not provide a complete drug-specific numerical validation table for these five agents. No absent analytical limit should be supplied by assumption.

The study did not validate a lethal threshold, impairment rule or administered-dose estimate. Preserve both specimen types, concentrations, units and collection times. A ratio of 1.8 or 0.69 cannot simply be applied to a new person to recover a known concentration at death.

For another matrix-sensitive comparison from this research, see pholcodine ratios with mixed earlier specimen types versus whole blood.

Primary source

Mantinieks D, Gerostamoulos D, Glowacki L, et al. Postmortem Drug Redistribution: A Compilation of Postmortem/Antemortem Drug Concentration Ratios. Journal of Analytical Toxicology. 2021;45:368–377. doi:10.1093/jat/bkaa107.

Failure to find a statistically significant decomposition-group difference did not establish that advanced putrefaction leaves drug concentrations unchanged. A Dutch autopsy study’s null comparisons must be read alongside its small advanced-decomposition groups and its use of postmortem site ratios rather than predeath measurements.

What population was actually studied?

de Groot and colleagues reviewed Netherlands Forensic Institute investigations from January 2010 through July 2020. Inclusion required a studied amphetamine-group drug or benzodiazepine to be quantified in both femoral and central blood. The datasets contained 112 amphetamine-group cases and 179 benzodiazepine-positive cases; individual compounds had different paired denominators.

Cases therefore needed sufficient material and quantitative results at both sites. The findings did not validate testing when decomposition left no usable blood. Nor did the investigators follow the same bodies prospectively through successive stages of decay.

Most stimulant observations were in early grades

For amphetamine, Table 5 listed 47 cases in decomposition grade I and 20 in grade II. There were only two in grade III, three in grade IV and two in grade VI. The overall decomposition comparison had p = 0.245.

MDMA had 26 grade-I and 11 grade-II cases, with one grade-V case. MDA had 22 grade-I and 11 grade-II cases, with one grade-VI case. Their decomposition comparisons had p = 0.242 and p = 0.135, respectively. These available graded observations did not exhaust every analyte’s full paired dataset.

None of those comparisons met the study’s corrected amphetamine-group significance threshold of p < 0.0045. A single advanced-grade observation, however, cannot characterize the range expected in that grade or demonstrate equivalence with early decomposition.

The benzodiazepine comparisons had similar coverage limits

Midazolam had 45 grade-I, 11 grade-II and two grade-III cases, with p = 0.072 for the decomposition comparison. Its metabolite α-hydroxymidazolam had 23, seven and one, respectively, with p = 0.884. The study reported no significant decomposition-group differences for the investigated benzodiazepines.

The authors specifically noted that decomposition was mostly limited to grades I and II and considered that limited range a possible explanation for the absent differences. They also acknowledged small subgroup sizes as a general limitation despite reviewing more than ten years of casework.

A stable ratio would not prove stable concentrations

The measured endpoint was central concentration divided by femoral concentration. Both concentrations could change without producing a comparable change in their ratio. No paired antemortem specimen established stability relative to life, and no controlled serial collection separated degradation from redistribution or fluid mixing.

The null statistical result therefore cannot support a claim that putrefaction is irrelevant, that either blood site preserved the original concentration, or that every drug behaves similarly.

Collection and laboratory handling were specified

Femoral blood was obtained after targeted dissection before internal examination. Central samples came from the right atrium or inferior vena cava with the heart in situ. Glass tubes contained sodium fluoride and sodium heparin; samples were frozen at −20°C and analyzed within three months after collection.

Screening was followed by quantitative UPLC–MS/MS. Those procedures establish how collected material was investigated. They do not reverse changes that occurred in the body before collection, and the study supplied no decomposition-specific correction formula.

How should the null result be used?

Retain the decomposition grade, subgroup count, analyte, collection site and statistical threshold. Distinguish failure to detect a difference from evidence that a clinically or forensically meaningful difference is absent. Neither the ratio nor drug detection alone establishes dose, impairment or cause of death.

The separate problem of unavailable specimens is illustrated by diphenhydramine cases in which decomposition left no blood for testing.

Primary source

de Groot ADE, Borra LCP, van der Hulst R, et al. Postmortem redistribution of amphetamines and benzodiazepines in humans: Important variables that might be influencing the central blood / peripheral blood ratio. Forensic Science International. 2023;353:111876. doi:10.1016/j.forsciint.2023.111876.

Higher femoral amphetamine concentrations were associated with lower cardiac-to-femoral ratios in a Dutch autopsy study. That finding did not establish that high concentrations were unchanged after death, or provide a formula for reconstructing an individual concentration during life.

Seventy-five amphetamine pairs, not 112 independent pairs

de Groot and colleagues reviewed Netherlands Forensic Institute investigations from January 2010 through July 2020. Their amphetamine-group dataset contained 112 cases involving amphetamine, MDMA or MDA quantified in both blood sites. Amphetamine itself contributed 75 pairs. Cases could contribute more than one analyte.

Femoral blood was obtained by sterile syringe after targeted dissection, before internal examination. Central blood came from the right atrium or inferior vena cava with the heart in place. Sodium-fluoride/sodium-heparin tubes were stored at −20°C and analyzed within three months of collection.

The ratio compared two postmortem sites collected at autopsy. There was no paired antemortem concentration establishing how far either result had moved from the value during life.

What changed across concentration quartiles?

Amphetamine quartiles and cardiac/peripheral ratios in Table 5.

Femoral concentration	Cases	Median ratio	Ratio range
0.0050–0.053 mg/L	18	2.4	1.2–4.4
0.061–0.19 mg/L	19	2.2	0.94–6.6
0.19–0.70 mg/L	19	1.7	1.1–3.3
0.70–39 mg/L	19	1.6	0.67–2.6

The highest quartile differed from the first and second quartiles in post-hoc comparisons, with p < 0.001 and p = 0.001, respectively. These met the study’s corrected significance threshold of p < 0.0045 for amphetamines. The published concentration boundaries are descriptive divisions of this dataset, not clinical or legal thresholds.

A median ratio of 1.6 did not mean equality between sites. Individual ratios within the highest quartile also crossed one. The association cannot be converted into a rule that every high result has a particular redistribution history.

Short survival was a possible explanation

The authors proposed that a short interval between dosing and death could leave less drug deposited in tissues, reducing the reservoir available to redistribute into central blood. That mechanism was not directly measured in each person. Route of administration could not be determined from the available amphetamine case records and was omitted from the statistical analysis.

The authors considered a high femoral concentration together with a ratio near one suggestive of limited redistribution, particularly if circumstances supported short survival. This remained a contextual inference, not validation of a numerical correction or an exact survival-time estimate.

Method performance and biological interpretation are separate

Routine screening was followed by quantitative UPLC–MS/MS. For amphetamine, the reported calibration limits were 0.005–1 mg/L; Table 2 listed accuracy deviation −11%, precision 7% and recovery 83%. These validation figures describe the measurement procedure. They do not validate the proposed survival-time mechanism or a concentration-to-dose relationship.

No corresponding significant concentration-quartile association was established for MDMA. MDA’s quartile comparison had p = 0.012, which did not meet the corrected threshold. The amphetamine finding should therefore retain its analyte-specific scope.

What should accompany a quoted ratio?

Preserve both original concentrations, collection sites, timing and the available circumstances. Do not divide an individual result by a quartile median to recover a presumed predeath concentration. Detection and a postmortem site ratio do not independently establish impairment or cause of death.

For another site-ratio limitation, see why a fentanyl ratio near one does not exclude postmortem change.

Primary source

de Groot ADE, Borra LCP, van der Hulst R, et al. Postmortem redistribution of amphetamines and benzodiazepines in humans: Important variables that might be influencing the central blood / peripheral blood ratio. Forensic Science International. 2023;353:111876. doi:10.1016/j.forsciint.2023.111876.

A risk ratio of 1.34 is not a 34% probability of an adverse event. It compares the event risk in a treatment group with the risk in its comparator. A 2025 meta-analysis of prescription stimulants reported that ratio for overall adverse events, but interpreting it requires the comparison risk, drug classes, follow-up and uncertainty.

The review included lisdexamfetamine and other amphetamines alongside methylphenidate. Its combined estimate should not be relabeled an amphetamine-only risk, an illicit-methamphetamine risk or an individual forecast.

What did the review include?

Oliva and colleagues published the meta-analysis in JAMA Network Open on May 9, 2025. It included 93 placebo-controlled randomized clinical trials and reported 16,382 participants overall. The included trials addressed ADHD and several other clinical conditions, as well as healthy-volunteer research.

ADHD predominated: the authors identified 77 trials, or 82.7%, involving ADHD alone. Trials differed in stimulant, formulation, dose, population and duration. Follow-up extended up to 52 weeks, but many studies were much shorter. The overall population count does not mean every participant contributed to every adverse-event or vital-sign analysis.

This was a synthesis of clinical trial reports. It did not administer a common methamphetamine dose or collect one standardized set of toxicology specimens. Prescription amphetamine formulations, lisdexamfetamine and methylphenidate should retain their individual names rather than being collapsed into methamphetamine.

What did the principal estimate mean?

The pooled risk ratio for overall adverse events was 1.34, with a 90% confidence interval of 1.27–1.41. This corresponds to an estimated 34% relative increase compared with placebo, not an increase of 34 percentage points.

For illustration only, if a comparison population had a 20% event risk, multiplying by 1.34 would give 26.8%, an absolute increase of 6.8 percentage points. If the comparison risk were 50%, the same multiplication would give 67%, an increase of 17 percentage points. Those hypothetical values explain the arithmetic; they are not the review’s observed pooled event rates.

A risk ratio alone therefore cannot supply a universal number needed to harm or a fixed absolute probability for a patient. The baseline risk and the relevance of the study population matter.

Why must the confidence level be preserved?

The paper reports 90% intervals and specifies a two-sided significance threshold of p < 0.10. Those are the study’s stated choices. Its intervals should not be quoted as 95% confidence intervals.

Confidence intervals describe statistical uncertainty around an estimated effect under the analytical assumptions. They are not a probability range for one person’s outcome. They also do not incorporate every concern about differences between trials or the transfer of a pooled finding to a different population.

Were lisdexamfetamine and other amphetamines separately considered?

Yes. The authors report that the overall-adverse-event association remained statistically significant when methylphenidate, lisdexamfetamine and other amphetamines were analyzed separately. That finding supports attention to the amphetamine-related evidence, but does not make the combined 1.34 ratio the estimate for each subgroup.

Likewise, separate significant comparisons with placebo do not establish that the stimulant classes have identical risks or that one is safer than another. Such comparisons require the relevant direct or appropriately modeled between-group analysis.

The review reported substantial variation in its overall adverse-event analysis, with I² = 67%. That statistic describes heterogeneity among study estimates. It is not the percentage of participants harmed and does not mean 67% of adverse events were caused by medication.

What were “adverse events” in this evidence?

The primary outcome concerned developing any reported adverse event. It did not mean that every event was severe, that every participant stopped medication, or that every reported symptom had an independently established drug cause.

The review separately analyzed decreased appetite, headache, insomnia, dry mouth, nausea, irritability and anxiety. It also examined vital signs. Combining these categories into an undifferentiated claim of “serious harm” would misstate the endpoint.

Adverse-event occurrence, severity, clinical importance and discontinuation are distinct questions. A trial can report more nonserious symptoms while reporting few serious events, and neither observation erases the other.

How should its cardiovascular findings be bounded?

The authors found higher pooled diastolic blood pressure and heart rate in stimulant groups, while the systolic-pressure comparison was nonsignificant. They judged the pooled vital-sign changes not clinically significant. That judgment concerns the measured average differences under the reviewed protocols.

It does not establish that no individual experienced a clinically important change, nor that rare cardiovascular outcomes are excluded over many years. The review itself distinguishes its controlled trial evidence, with follow-up no longer than about one year, from longer observational and pharmacovigilance evidence.

Those evidence types have different strengths and limitations. A spontaneous report cannot automatically establish drug causation; a short randomized trial cannot automatically resolve rare long-term risks.

Did the review establish an absence of misuse or psychosis risk?

No. The authors describe misuse potential and the emergence of psychosis as understudied and call for more standardized assessment. The absence of directly identified addiction behaviors in the included trials is not proof that misuse cannot occur outside those controlled settings.

Drug liking, dependence, diversion, psychiatric symptoms and an adverse-event count are different outcomes. An observed result on one cannot stand in for a validated estimate of every other outcome.

What is the defensible conclusion?

This historical meta-analysis found a higher reported adverse-event risk with prescription stimulants than with placebo across its included trials. The numerical estimate is relative, pooled across classes and accompanied by 90% uncertainty intervals and substantial heterogeneity.

For an individual forensic question, it supplies neither an amphetamine concentration threshold nor proof that a particular symptom, crash or psychiatric episode was caused by the drug. Preserve the formulation, population, endpoint and observation period before transferring a group estimate to a case.

Scientific source

Oliva HNP, Prudente TP, Mayerson TF, et al. Safety of Stimulants Across Patient Populations: A Meta-Analysis. JAMA Network Open. 2025;8(5):e259492. doi:10.1001/jamanetworkopen.2025.9492. Full-text meta-analysis. Historical synthesis of placebo-controlled human trials across stimulant classes.